Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-08-02
2005-08-02
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S003000
Reexamination Certificate
active
06924282
ABSTRACT:
A sodium salt of Compound A is disclosed, wherein Compound A is of formula:Compound A is an HIV integrase inhibitor useful for preventing or treating HIV infection, for delaying the onset of AIDS, and for treating AIDS.
REFERENCES:
patent: 4996213 (1991-02-01), Mendes et al.
patent: 5294620 (1994-03-01), Ratcliffe et al.
patent: 5945431 (1999-08-01), Jin et al.
patent: 6262055 (2001-07-01), Young et al.
patent: 6294547 (2001-09-01), Oka et al.
patent: 6306891 (2001-10-01), Selnick et al.
patent: 6380249 (2002-04-01), Young et al.
patent: 2003/0055071 (2003-03-01), Anthony et al.
patent: WO 96/25399 (1996-08-01), None
patent: WO 98/11073 (1998-03-01), None
patent: WO 98/13350 (1998-04-01), None
patent: WO 99/10347 (1999-03-01), None
patent: WO 99/32450 (1999-07-01), None
patent: WO 01/00578 (2001-01-01), None
patent: WO 02/04443 (2002-01-01), None
patent: WO 02/06246 (2002-01-01), None
patent: WO 02/30930 (2002-04-01), None
patent: WO 03/035076 (2003-05-01), None
patent: WO 03/035077 (2003-05-01), None
L. Chan et al., “Discovery of 1,6-Naphthyridines as a Novel Class of Potent and Selective Human Cytomegalovirus Inhibitors”, J. Med. Chem., vol. 42, No. 16, pp. 3023-3025 (1999).
L.A. Lasky et al., “Delineation of a Region of the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein Critical for Interaction with the CD4 Receptor”, Cell, vol. 50, pp. 975-985 (1987).
L. Ratner et al., “Complete Nucleotide Sequence of the AIDS Virus, HTLV-III”, Nature, vol. 313, pp. 277-284 (1985).
H. Toh et al., “Close Structural Resemblance Between Putative Polymerase of a Drosophila Transposable Genetic Element 17.6 and pol gene product of Moloney Murine Leukaemia Virus”, The EMBO Journal, vol. 4, No. 5, pp. 1267-1272 (1985).
M.D. Power et al., “Nucleotide Sequence of SRV-1, Type D Simian Acquired Immune Deficiency Syndrome Retrovirus”, Science, vol. 231, pp. 1567-1572 (1986).
L.H. Pearl et al., “A Structural Model for the Retroviral Proteases”, Nature, vol. 329, pp. 351-354 (1987).
Derwent Abstract No. 97-048296/05 (Abstract of JP 08301849-A, Takeda Chem. Ind. Ltd., “New Heterocyclic Carboxamide Derivs.—Useful in Pharmaceuticals as Tachykinin Receptor Inhibitors”).
Chemical Abstracts No. 33-2525; (Abstract of Otiai et al., “Synthesis of 2.5 Naphthyridine Derivatives, II”, J. Pharm. Soc. Japan, vol. 58, pp. 764-770 (1938)).
CAPLUS Accession No. 2001:923611, Kiyama et al., “Dual Divalent Metal Ion Chelators as HIV Integrase Inhibitors”, Abstract of WO 01/95905, Assignee: Shionogi & Co., Ltd. (2001).
Abstract of WO 02/070486 from http://ipdl.wipo.int (Fuji et al., “Nitrogen-Containing Heteroaryl Compounds Having HIV Integrase Inhibitory Activity”, Assignee: Shionogi & Co., Ltd.).
Abstract of WO 02/070491 from http://ipdl.wipo.int (Fuji et al., “Nitrogenous Heteroaromatic Ring Derivative Having HIV Integrase Inhibitory Activity”, Assignee: Shionogi & Co., Ltd.).
Anthony Neville J.
Lepore John V.
Mahajan Amar J.
Xu Wei
Camara Valerie J.
Habte Kahsay
Merck & Co. , Inc.
Walton Kenneth R.
Wilson James O.
LandOfFree
Sodium salt of an HIV integrase inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sodium salt of an HIV integrase inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sodium salt of an HIV integrase inhibitor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3512221